Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990 Nov;87(21):8267-71.
doi: 10.1073/pnas.87.21.8267.

Extracellular ATP in T-lymphocyte activation: possible role in effector functions

Affiliations

Extracellular ATP in T-lymphocyte activation: possible role in effector functions

A Filippini et al. Proc Natl Acad Sci U S A. 1990 Nov.

Erratum in

  • Proc Natl Acad Sci U S A 1991 Aug 1;88(15):6899

Abstract

We hypothesized that cytolytic T lymphocytes (CTL) may utilize extracellular ATP (ATPo) during the effector phase of the CTL-target cell interactions and that CTL could be the source of ATPo. It is demonstrated here that incubation of CTL with activating ligands [Con A or monoclonal antibody (mAb) to the T-cell antigen receptor (TCR)] results in the extracellular Ca2(+)-independent accumulation of the ATPo. The addition of the ATP-degrading enzymes into the mixture of CTL and target cells results in a strong inhibition of the CTL-mediated, TCR-triggered lethal-hit delivery to the target cell. In a parallel control experiment, the employed enzymes did not affect target cell-induced, TCR-triggered exocytosis of granules from CTL. Thus, the removal of ATPo with enzymes does not interfere with the activation of CTL by the target cell but does block lytic events. Cloned helper T lymphocytes also accumulate ATPo after incubation with anti-TCR mAb or Con A, suggesting the possibility that ATPo, which acts in concert with ectoprotein kinases and/or purinergic receptors, may be of general use as a messenger in cellular interactions of T lymphocytes.

PubMed Disclaimer

References

    1. J Immunol. 1985 Jun;134(6):3994-4000 - PubMed
    1. Proc Natl Acad Sci U S A. 1984 Dec;81(24):7922-6 - PubMed
    1. FEBS Lett. 1985 Jun 17;185(2):323-7 - PubMed
    1. J Immunol. 1986 Jan;136(1):23-7 - PubMed
    1. Biochem J. 1986 Jan 15;233(2):309-19 - PubMed

LinkOut - more resources